HOUSTON, Sept. 29, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced that it has appointed Lippe Taylor Group as its
consumer health public relations and customer engagement agency.
The partnership aims to support the launch of the Rapid
Acoustic Pulse ("RAP") device through connected experiences
within aesthetic practices and across digital channels.
Soliton's selection of Lippe Taylor Group is another step in
advancing the U.S. commercialization of the Rapid Acoustic Pulse
device in the first half of 2021.
"Lippe Taylor Group has a deep understanding of the aesthetics
industry and will be important in supporting our efforts to create
brand loyalty with both our practitioners and future tattoo removal
and cellulite reduction patients (should we receive clearance from
the FDA for cellulite)" commented Christopher Capelli, MD, founder, President and
CEO of Soliton. "We look forward to working closely with Lippe
Taylor Group and welcome them to the Soliton family."
"We are excited by the future of the Rapid Acoustic Pulse
technology in accelerating and optimizing patient outcomes," said
Paul Dyer, Chief Executive Officer
of Lippe Taylor Group. "Once we learned about the technology and
the team at Soliton, we saw enormous potential, and through this
partnership we hope to leverage our expertise and relationships in
medical aesthetics to help Soliton achieve that potential."
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
About Lippe Taylor Group
For over 20 years Lippe Taylor Group (LTG) has been a fiercely
independent and highly influential digital PR and marketing agency
representing brands determined to understand, reach, and move
people to take action. LTG specializes in engaging brand
communications programs across earned media, digital, and social
media. Founded by former magazine editor Maureen Lippe,
Lippe Taylor's legacy is launching
award-winning, innovative campaigns for some of the world's most
significant and successful brands in healthcare and consumer
sectors. LTG was named an Agency of the Year in the PR industry in
2019.
About Soliton,
Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer
Center. The Company's first FDA cleared commercial product will use
rapid pulses of acoustic shockwaves as an accessory to lasers for
the removal of unwanted tattoos. The Company is based in
Houston, Texas, and is actively
engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the
market. The Company believes this "Soliton" method has the
potential to lower tattoo removal costs for patients, while
increasing profitability to practitioners, compared to current
laser removal methods. Soliton has completed a clinical study
using the RAP device to improve the appearance of cellulite and is
investigating potential additional capabilities of the RAP
technology. The device is currently cleared in the United States only for use in tattoo
removal and is not yet cleared for use to address cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, our ability to successfully
launch our product and achieve clearance of our cellulite reduction
technology from the FDA. These statements relate to future
events, future expectations, plans and prospects. Although Soliton
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, actual results or
outcomes may prove to be materially different from the expectations
expressed or implied by such forward-looking statements. Soliton
has attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' "would," ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
in our filings with the Securities and Exchange Commission ("SEC"),
including under the heading " Risk Factors" in the Form 10-K for
year ended December 31, 2019 filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-selects-lippe-taylor-group-as-its-public-relations-and-customer-engagement-agency-301138242.html
SOURCE Soliton, Inc.